Novem Group Invests $1.09 Million in United Therapeutics Corporation $UTHR

Novem Group purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,230 shares of the biotechnology company’s stock, valued at approximately $1,087,000.

Several other hedge funds have also recently bought and sold shares of UTHR. Evergreen Capital Management LLC boosted its position in United Therapeutics by 4.9% during the fourth quarter. Evergreen Capital Management LLC now owns 13,588 shares of the biotechnology company’s stock worth $6,621,000 after purchasing an additional 633 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of United Therapeutics by 169.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,012 shares of the biotechnology company’s stock valued at $25,343,000 after buying an additional 32,689 shares in the last quarter. Krilogy Financial LLC raised its stake in shares of United Therapeutics by 68.4% during the 4th quarter. Krilogy Financial LLC now owns 1,753 shares of the biotechnology company’s stock worth $830,000 after buying an additional 712 shares during the last quarter. Earned Wealth Advisors LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth $275,000. Finally, Seeds Investor LLC boosted its position in shares of United Therapeutics by 9.7% in the 4th quarter. Seeds Investor LLC now owns 1,476 shares of the biotechnology company’s stock worth $719,000 after buying an additional 130 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. HC Wainwright upped their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Finally, TD Cowen raised their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: New clinical and program data to be presented at ISHLT (ARTISAN and PHINDER interim analyses) highlight earlier detection/management of pulmonary hypertension, right‑ventricular improvement with high‑dose treprostinil, and progress on lung donor expansion/xenotransplantation — supports pipeline value and longer‑term revenue upside. Read More.
• Positive Sentiment: Analyst sentiment remains constructive with several recent price‑target raises and a consensus “Moderate Buy” and average target around $601.50 — provides valuation support if clinical readouts impress.
• Positive Sentiment: Discussion that the bull case for UTHR could materially change if miroliverELAP obtains FDA RMAT status — a regulatory win like RMAT would be a strong catalyst for re‑rating the pipeline. Read More.
• Neutral Sentiment: A comparative valuation article (CPRX vs UTHR) offers context for value investors but is unlikely to move UTHR materially on its own. Read More.
• Neutral Sentiment: Asset Management One modestly trimmed its stake (down ~5.1%), a small institutional reweighting rather than a major flow signal. Read More.
• Neutral Sentiment: Reports of unusually large options activity indicate elevated short‑term trading/hedging interest — this can amplify intraday moves but is directionally ambiguous. Read More.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.49M on Apr 20), reducing her stake by ~19% — a high‑profile insider sale that often raises investor concern about near‑term sentiment. Read More.
• Negative Sentiment: CFO James Edgemond sold 10,000 shares (~$5.78M) on Apr 20, leaving a significantly smaller holding — multiple senior exec sales in quick succession increase perceived selling pressure. Read More.
• Negative Sentiment: Additional director insider sale (~$578.9k) and prior smaller CEO disposals add to the pattern of recent insider liquidations, which can weigh on near‑term stock sentiment. Read More.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $470.95, for a total transaction of $10,596,375.00. The SEC filing for this sale provides additional information. In the last three months, insiders sold 420,795 shares of company stock valued at $224,011,581. Company insiders own 10.30% of the company’s stock.

United Therapeutics Trading Up 0.0%

United Therapeutics stock opened at $573.46 on Wednesday. The stock has a market cap of $25.13 billion, a PE ratio of 20.55, a P/E/G ratio of 1.63 and a beta of 0.75. The stock has a 50-day moving average price of $530.74 and a 200 day moving average price of $492.11. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the company posted $6.19 EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post 27.93 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.